Sesamin medicine for relieving allergic diarrhea based on intestinal flora-short-chain fatty acid pathway and application of sesamin medicine

Sesamin regulates intestinal flora to increase short-chain fatty acid production, addressing the inefficiencies of current treatments by alleviating allergic diarrhea symptoms and promoting intestinal health.

CN119074719APending Publication Date: 2024-12-06SHANDONG AGRICULTURAL UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411416664.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-11
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

Current treatments for allergic diarrhea, such as antihistamines and anti-inflammatory drugs, suffer from significant side effects, drug resistance, and high costs, necessitating a safe and efficient natural compound to regulate intestinal flora and increase short-chain fatty acid production.

Method used

The use of sesamin, a lignan compound from sesame seeds and peppers, to regulate intestinal flora and increase the production of short-chain fatty acids, including acetic, propionic, butyric, isobutyric, and isovaleric acids, through fermentation of incompletely digested polysaccharides.

Benefits of technology

Sesamin effectively alleviates allergic diarrhea symptoms by balancing intestinal flora, reducing mast cell degranulation, and normalizing immune cell differentiation, while increasing short-chain fatty acid production and receptor expression, thus improving intestinal health.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119074719A_ABST
    Figure CN119074719A_ABST
Patent Text Reader

Abstract

The invention discloses a sesamin medicine for relieving allergic diarrhea based on an intestinal flora-short chain fatty acid pathway and application of the sesamin medicine, and belongs to the technical field of biological medicine. The sesamin is a lignan compound in sesame seeds and / or Chinese prickly ash; the sesamin regulates and controls the increase of the yield of the short-chain fatty acid by regulating and controlling intestinal flora. The sesamin promotes proliferation of probiotics and inhibits growth of pathogenic bacteria, so that the yield of short-chain fatty acid is increased. The process enhances the expression level of a short-chain fatty acid receptor, promotes balanced differentiation of immune T cells, inhibits degranulation of mast cells, relieves intestinal tissue damage and regulates the level of inflammatory factors. Experimental results show that sesamin can significantly relieve symptoms of diarrhea and watery stool of mice, inhibit abnormal decrease of body temperature and reduce clinical scores of diseases. The invention expands the application of sesamin products as drugs for relieving allergic diarrhea.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a sesamin medicine for alleviating allergic diarrhea based on an intestinal flora-short-chain fatty acid pathway and application thereof, belonging to the technical field of biomedicine. Background Art

[0002] Allergic diarrhea is an intestinal immune response caused by allergens in the environment or food, which is specifically manifested as symptoms such as diarrhea and watery stools. The incidence rate has continued to increase in recent years. Common causes include food allergens, environmental allergens (such as pollen, dust mites, pet dander, etc.), drug allergens (such as antibiotics, non-steroidal anti-inflammatory drugs), autoimmune diseases (such as eosinophilic esophagitis) and other hypersensitivity reactions (such as asthma, mastocytosis, seasonal allergies and immune stress). Current conventional treatment methods mainly rely on antihistamines, anti-inflammatory drugs and immunomodulators. However, these methods often have problems such as large toxic side effects, strong drug resistance and high cost. Therefore, it has become an urgent need to develop an efficient, low-cost and safe natural compound to accurately relieve allergic diarrhea. In view of this, this invention is specially proposed.

[0003] Allergic diarrhea is closely related to intestinal lesions, in which intestinal flora and its metabolic activities play a key role. Studies have shown that intestinal flora disorders can damage the intestinal barrier function and thus cause allergic diarrhea. By regulating the composition of intestinal flora and its metabolite levels, especially the levels of short-chain fatty acids (such as acetate, propionate, and butyrate), the related symptoms can be effectively alleviated. Short-chain fatty acids maintain intestinal health by activating their corresponding receptors, regulating the balance of immune cells, and providing energy to epithelial cells. Therefore, increasing the level of short-chain fatty acids has become an important strategy to improve allergic diarrhea. Supplementing dietary factors, probiotics and prebiotics can help optimize the flora structure, regulate metabolic activities, directly regulate the host intestinal immune balance, enhance disease resistance, and thus relieve symptoms.

[0004] Polyphenols are secondary metabolites widely found in plants. They are characterized by multiple phenolic hydroxyl functional groups connected to benzene rings. They are common food-borne dietary factors and have been proven to have many benefits for human health, especially in regulating the structure of intestinal flora and maintaining intestinal homeostasis. Studies have shown that polyphenols can effectively regulate the structure and metabolic activity of intestinal flora and help restore the body's microecological balance. Sesamin is a lignan mainly derived from sesame seeds and peppers, with excellent immunomodulatory effects and biological activity. Summary of the invention

[0005] In order to solve the current problems, the present invention provides a sesamin product, which effectively improves or alleviates allergic diarrhea by regulating the intestinal flora structure and increasing the production of short-chain fatty acids.

[0006] To achieve the above object, the present invention adopts the following technical solution:

[0007] Application of sesamin in increasing the production of short-chain fatty acids, wherein the sesamin is a lignan compound in sesame seeds and / or peppers;

[0008] The sesamin regulates the intestinal flora and thus increases the production of short-chain fatty acids.

[0009] The English name of sesamin is (+)-sesamin, the molecular weight is 354.35 g / mol, and the chemical formula is C 20 H 18 O6, Chemical Abstracts Service No. (CAS No.) is 607-80-7, and its physical characteristics are odorless white powder, and its structure is shown in Formula I:

[0010]

[0011] In one embodiment of the present invention, the intestinal flora includes probiotics that relieve allergic diarrhea and / or pathogenic bacteria that induce allergic diarrhea.

[0012] In one embodiment of the present invention, the probiotics for alleviating diarrhea include at least one of Prevotellaceae and Muribacillus (Muribaculaceae);

[0013] And / or, the pathogenic bacteria inducing allergic diarrhea include at least one of Bacteroides, Enterobacteriaceae, Fusobacteriaceae, Lachnoclostridium, Blautia and Acidaminococcaceae.

[0014] In one embodiment of the present invention, the short-chain fatty acids are produced by intestinal flora through fermentation of incompletely digested polysaccharides; preferably, the short-chain fatty acids include at least one of acetic acid, propionic acid, butyric acid, isobutyric acid and isovaleric acid.

[0015] Another object of the present invention is to protect the use of sesamin in the preparation of a drug for treating allergic diarrhea, wherein the sesamin is a lignan compound present in sesame seeds and / or peppers;

[0016] The sesamin mentioned above plays a role in regulating allergic diarrhea by increasing the production of short-chain fatty acids;

[0017] In one embodiment of the present invention, sesamin is used in the preparation of a drug for alleviating intestinal barrier damage caused by allergic diarrhea;

[0018] In one embodiment of the present invention, sesamin is used in the preparation of a drug for alleviating intestinal barrier damage caused by allergic diarrhea;

[0019] In one embodiment of the present invention, sesamin is used in the preparation of a drug for alleviating imbalance in immune T cell differentiation caused by allergic diarrhea.

[0020] Another object of the present invention is to protect a drug for preparing a drug for treating allergic diarrhea, wherein the drug comprises the sesamin according to claim 1 or 2 and a carrier for delivering sesamin.

[0021] In one embodiment of the present invention, the carrier for delivering sesamin comprises at least one of nanoparticles, emulsions, capsules, compressed candies, gels and liposomes.

[0022] In one embodiment of the present invention, auxiliary materials are also included; the auxiliary materials include at least one of fillers, emulsifiers, adhesives, stabilizers, anti-caking agents, flavoring agents and thickeners.

[0023] In one embodiment of the present invention, the drug contains an effective amount of 0.1 wt.%-99.9 wt.% of sesamin.

[0024] In one embodiment of the present invention, the drug reduces the abnormally elevated transcription levels of Th2 cell marker gene Gata3 and Th17 cell marker gene Rorc, and increases the abnormally reduced transcription levels of Th1 cell marker gene T-bet and Treg cell marker gene Foxp3.

[0025] In one embodiment of the present invention, the mouse is a Balb / c strain mouse, and the diarrhea modeling method is as follows: Figure 1 As shown, the details are as follows:

[0026] (I) Phosphate buffered saline containing 50 μg of ovalbumin and aluminum hydroxide adjuvant was injected intraperitoneally once every 7 days for a total of 3 injections for 14 days.

[0027] (II) Starting from the 21st day, 50 mg of ovalbumin was administered intragastrically every two days for 5 consecutive times.

[0028] (III) After oral administration of 100 mg of ovalbumin on day 32, the clinical symptoms of mice were observed.

[0029] (IV) Fecal samples were collected, mice were sacrificed and tissue samples were collected for index detection.

[0030] In one embodiment of the present invention, the sesamin product capable of relieving allergic diarrhea should include at least one of the following (a) to (f):

[0031] (a) Alleviation of weight loss and abnormal rectal temperature in diarrhea model mice;

[0032] (b) Alleviate symptoms of watery stool, abnormal stool color, and foul stool odor in diarrhea model mice.

[0033] (d) Reduce the abnormally elevated transcription levels of Gata3 (a marker gene for Th2 cells) and Rorc (a marker gene for Th17 cells), and increase the abnormally decreased transcription levels of T-bet (a marker gene for Th1 cells) and Foxp3 (a marker gene for Treg cells).

[0034] (e) Reduce the key indicators of the microbiome in allergic diarrhea diseases: the abnormally elevated ratio of Enterobacteriaceae to Bacteroidaceae.

[0035] (f) Alleviate the degree of intestinal damage and inhibit the rate of mast cell degranulation.

[0036] In one embodiment of the present invention, the Illumina NovaSeq 6000 platform is used to sequence the species and abundance of fecal flora using the 16s rRNA method.

[0037] In one embodiment of the present invention, high-resolution and high-performance gas chromatography-mass spectrometry is used to detect short-chain fatty acid substances in feces.

[0038] Beneficial effects of the present invention:

[0039] (1) Oral administration of sesamin has a significant inhibitory effect on the clinical symptoms of allergic diarrhea: symptoms including watery stools, weight loss, decreased rectal temperature, and increased clinical disease scores were alleviated.

[0040] (2) Oral administration of sesamin can regulate the expression of immune cell marker genes: it increases the transcription levels of Th1 cell marker gene T-bet and Treg cell marker gene Foxp3, and reduces the abnormal increase of Th2 cell marker gene Gata3 and Th17 cell marker gene Rorc, thereby maintaining the differentiation balance of intestinal immune cells.

[0041] (3) Oral administration of sesamin can significantly inhibit the degranulation rate of mast cells in the intestine.

[0042] (4) The characteristic flora at the family level in the diarrhea model group included Bacteroides, Enterobacteriaceae, Fusobacteriaceae, Lachnoclostridium, Blautia, and Acidaminococcaceae. The characteristic flora at the family level in the sesamin-administered group were Prevotellaceae and Bacteroides.

[0043] (5) The abundance of Prevotellaceae and Muribacillus (Muribaculaceae), which have a relieving effect on allergic diarrhea, decreased in the model group compared with the control group, while their abundance increased in the sesamin-treated group.

[0044] (6) The abundance of Enterobacteriaceae, Fusobacteriaceae, Lachnoclostridium, Blautia and Acidaminococcaceae, which promote allergic diarrhea, increased significantly in the model group and decreased in the sesamin-treated group.

[0045] (7) Compared with the control group and the model group, the levels of short-chain fatty acids such as acetate, propionate, butyrate, isobutyrate, and isovaleric acid in the feces of mice treated with sesamin were significantly increased.

[0046] (8) There is a significant and strong correlation between changes in fecal abundance and short-chain fatty acids levels, indicating that short-chain fatty acids may be an important way to regulate the flora and exert physiological regulatory effects.

[0047] (9) The expression level of short-chain fatty acid receptors in the intestine of mice in the diarrhea model group was significantly decreased, while the expression of short-chain fatty acid receptors in the intestine of mice in the sesamin treatment group was significantly increased. BRIEF DESCRIPTION OF THE DRAWINGS

[0048] Figure 1 Modeling process for allergic diarrhea in mice;

[0049] Figure 2 This is a diagram showing the effect of sesamin on the clinical symptoms of mice with allergic diarrhea;

[0050] Figure 3 This is a diagram showing the effect of sesamin on T cell differentiation marker genes in mouse intestinal immunity;

[0051] Figure 4 This is the effect of sesamin on the degranulation rate of mouse mast cells;

[0052] Figure 5 This is a diagram showing the effect of sesamin on the structure and composition of the intestinal flora in mice;

[0053] Figure 6 This is the effect of sesamin on the abundance of characteristic flora in the intestinal flora of mice;

[0054] Figure 7 This is a diagram showing the effect of sesamin on the level of short-chain fatty acids in mouse feces and the expression of short-chain fatty acid receptors in the intestine;

[0055] Figure 8 This is a clustering heat map of the correlation between intestinal flora-short-chain fatty acids and flora-disease biological factors. DETAILED DESCRIPTION

[0056] The following embodiments are provided for a better understanding of the present invention and are not limited to the best implementation mode. Other embodiments obtained without creative work based on the embodiments of the present invention and without creative work all fall within the scope of protection of the present invention.

[0057] Example 1: Effect of Sesamin on Allergic Diarrhea Clinical Symptoms

[0058] Experimental method: After one week of adaptive culture, 30 female Balb / c mice were randomly divided into a control group, a model group, and a sesamin treatment group (40 mg / kg). On days 0, 7, and 14, 50 μg of ovalbumin (emulsified with aluminum hydroxide adjuvant) was intraperitoneally injected into the control group and the treatment group, and an equal volume of blank buffer was injected into the control group. On days 21, 23, 25, 27, and 29, mice in the model group and the treatment group were gavaged with 50 mg of OVA, and on day 32, 100 mg of OVA (twice 50 mg) was gavaged for stimulation, and mice in the control group were gavaged with an equal volume of drinking water. From day 21 to day 32, the treatment group was gavaged with 10, 20, and 40 mg / kg of sesamin suspension daily, and mice in the model group and the control group were gavaged with a placebo. If OVA and sesamin were gavaged on the same day, sesamin was given 1 hour before gavage of OVA. After stimulation on day 32, the perianal and diarrhea symptoms of the mice were observed.

[0059] Experimental results: No mice died abnormally in the experiment. Figure 2 As shown, by the end of the 32nd day of the provocation treatment, the OVA-induced model group mice showed watery and foul-smelling feces and obvious perianal adhesions, compared with the dark brown and compact feces of the control group. In contrast, the feces of the mice in the OVA+sesamin group were darker in color, more formed, lower in water content, and lighter in odor, and the diarrhea symptoms were significantly improved. Sesamin effectively alleviated the diarrhea symptoms caused by allergens.

[0060] Example 2: Effect of Sesamin on Allergic Diarrhea-Induced Imbalance in Intestinal Immune Cell Differentiation

[0061] Experimental methods: Total RNA was extracted from mouse ileum using a commercial kit, followed by removal of genomic DNA (gDNA) and synthesis of cDNA. Primers were designed and synthesized for transcription factors T-bet, Gata3, Foxp3, and RORc as specific probes indicating the differentiation levels of Th1, Th2, Treg, and Th17 immune cells, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal reference gene. Fluorescence quantitative polymerase chain reaction analysis was then performed to evaluate gene expression (sample number 3).

[0062] Experimental results: Transcription factors T-bet, Gata3, Foxp3 and RORc are specific markers of Th1, Th2, Treg and Th17 cells, respectively. In a healthy body, the ratio of Th1 / Th2 (T-bet / Gata3) and Treg / Th17 (Foxp3 / Rorc) remains stable. However, external stimuli may disrupt this balance, leading to polarization and differentiation of T cells and possibly causing disease. qRT-PCR analysis ( Figure 3 ) showed that in the diarrhea model group, the expression of T-bet and Foxp3 in the intestine was reduced, while the expression of Gata3 and Rorc was increased. Sesamin treatment significantly alleviated these abnormal gene expressions.

[0063] Example 3: Effect of Sesamin on Alleviating Intestinal Mast Cell Degranulation

[0064] Experimental method: The paraffin-embedded ileum was cut into 5 μm thick slices, dewaxed and stained with toluidine blue dye. The slices were dehydrated and sealed, and observed under a microscope to determine the proportion of mast cell degranulation.

[0065] The experimental results are as follows Figure 4 As shown, compared with the control group, the intestinal thickness of diarrheal mice decreased significantly, the structure was damaged, and the degree of mast cell degranulation, which is closely related to allergic diseases, increased significantly (from 29.89% in the control group to 61.78%). Sesamin-treated mice significantly alleviated the mast cell degranulation rate (to 36.58%) and allergic diarrhea damage.

[0066] Example 4: Effect of Sesamin on Allergic Diarrhea-Induced Intestinal Flora Disturbance

[0067] Experimental methods: Fresh feces of mice were collected, and DNA was extracted from fresh fecal samples of mice using a high-purity fecal DNA isolation kit. The V3-V4 region of the 16S rRNA gene was amplified using barcoded universal bacterial primers: forward (ACTCCTACGGGAGGCAGCA) and reverse (GGACTACHVGGGTWTCTAAT). The samples were sequenced on the Illumina NovaSeq 6000 platform. The sequences were filtered, denoised, spliced ​​and classified into operational taxonomic units (OTUs). The total reads of the samples were cleaned, quality controlled, and standardized to determine the relative abundance at the family or genus level. The principal coordinate analysis (PCoA) was used to evaluate the differences in bacterial abundance between different samples, and the PLS-DA analysis was applied to verify the rationality of the samples. The similarities between the samples were explored by cluster dendrograms. LefSe analysis was used to screen the characteristic bacterial communities in different samples, and the bar graph showed the differences in bacterial abundance at the family and genus levels among the groups. By analyzing the relative abundance of Enterobacteriaceae / Bacteroidetes, which are hallmarks of allergic diseases, the effect of sesamin on alleviating dysbiosis caused by diarrhea was explored.

[0068] Experimental results: Figure 5 The principal coordinate analysis (PCoA) of A showed that the dimensionality reduction positions of the control group and the treatment group overlapped, indicating that the microbial composition of the two groups was similar, while the model group showed obvious clustering, indicating that it had significant biological differences from the other two groups. Cluster tree analysis further confirmed the conclusion of PCoA analysis, that is, the six samples in the model group had obvious clustering similarities, while the sesamin treatment group and the control group were cross-clustered together, indicating that their microbial composition was more similar. Figure 5 PLS-DA analysis of B showed that the distribution differences among the groups were significant, indicating that the samples were grouped reasonably and the biological differences were significant. Figure 5 LefSe analysis of C revealed characteristic microorganisms at different taxonomic levels (phylum to genus) (linear discriminant analysis score > 4.0), focusing on the microbial community characteristics of the model group and the sesamin treatment group. Figure 5CE), the characteristic flora of the diarrhea model group included Bacteroides, Enterobacteriaceae, Fusobacteriaceae, Lachnoclostridium, Blautia and Acidaminococcaceae; the characteristic flora of the sesamin treatment group were Prevotellaceae and Bacteroides; in the model group, the abundance of Prevotellaceae, Muribaculaceae and Odoribacter, which have the effect of allergic diarrhea relief, decreased, while in the sesamin treatment group, the abundance increased. Enterobacteriaceae, Fusobacteriaceae, Lachnoclostridium, Blautia, and Acidaminococcaceae, which promote allergic diarrhea, increased significantly in the model group, but decreased in abundance in the sesamin-treated group ( Figure 6 ). The Enterobacteriaceae / Bacteroidetes family, a hallmark of allergic diseases, increased 4.14 times in the model group compared with the control group, while the sesamin-treated group decreased by 93.67% compared with the model group, indicating that sesamin effectively alleviated the imbalance of flora and disease characteristics associated with allergic diarrhea.

[0069] Example 5: Sesamin effectively alleviates the reduction in short-chain fatty acid production and abnormal expression of its receptors caused by allergic diarrhea

[0070] Experimental method: Fresh feces of mice were collected and short-chain fatty acids (SCFA) in feces were qualitatively and quantitatively analyzed by gas chromatography-mass spectrometry (GC-MS). Internal and external standards were used for double inspection to ensure the correlation coefficient (R 2 ) was greater than 0.99. The differences and similarities of each sample were evaluated by principal coordinate analysis (PCoA). The transcription levels of short-chain fatty acid receptor genes Gpr41, Gpr43, and Gpr109A in the intestine were detected using the qRT-PCR method as in Example 2.

[0071] Experimental results: PCoA analysis of mouse fecal SCFAs ( Figure 7 A) shows that the samples within the group are closely clustered, while the component samples are located in different positions. This indicates that the samples within the group have high similarity, but there are significant differences between the samples in the groups. C-MS analysis ( Figure 7B) showed that compared with the control group, the levels of acetic acid (AA) and propionic acid (PA) in the allergic diarrhea model group were significantly reduced, and the other SCFAs did not change significantly. In contrast, compared with the model group, sesamin treatment significantly increased the production of AA, PA, butyric acid (BA), isobutyric acid (IBA), and isovaleric acid (IVA). qRT-PCR analysis showed ( Figure 7 CE), the mRNA expression levels of intestinal short-chain fatty acid receptors Gpr41, Gpr43 and Gpr109A in the model group were significantly reduced, while those in the sesamin treatment group were significantly increased. Short-chain fatty acids are important metabolites of intestinal flora to maintain intestinal health, and sesamin can effectively alleviate the metabolic activity disorder of flora associated with allergic diarrhea.

[0072] Example 6: Correlation analysis between intestinal flora and short-chain fatty acids and intestinal flora and clinical indicators in mice with allergic diarrhea

[0073] Experimental method: R package was used to perform heat map analysis of flora-short-chain fatty acids and flora-disease indicators through Spearman rank correlation coefficient to intuitively display the correlation and significance. In the flora-short-chain fatty acid heat map, each row represents a short-chain fatty acid, and each column corresponds to a characteristic flora associated with allergic diarrhea. Positive correlation is represented by red, negative correlation is represented by blue, and color intensity and significance mark (* represents p < 0.05) intuitively display the possible association between factors. The results are shown in Figure 8 .

[0074] Experimental results: Analysis of the flora-short acid heat map shows that Prevotellaceae, Muribaculaceae and Odoribacter, which have the effect of relieving allergic diarrhea, are positively correlated with the production of short-chain fatty acids, while pathogenic bacteria Enterobacteriaceae, Fusobacteriaceae, Lachnoclostridium, Blautia and Acidaminococcaceae are negatively correlated. This shows that there is a significant correlation between the abundance of intestinal flora and the production of short acids. Sesamin can relieve the damage caused by allergic diarrhea by intervening in the structure of intestinal flora and increasing the production of short-chain fatty acids.

[0075] Analysis of microbiota-disease factors showed that Prevotellaceae, Muribaculaceae, and Odoribacter were positively correlated with disease-alleviating factors and negatively correlated with disease-aggravating factors; factors that aggravated allergic diarrhea included mast cell degranulation rate, Th2 cell differentiation marker gene Gata3, and Th17 cell marker gene Rorc. Factors that alleviated allergic diarrhea included short-chain fatty acid receptor expression levels, Th1 and Treg cell differentiation marker genes T-bet and Foxp3. Pathogenic bacteria Enterobacteriaceae, Fusobacteriaceae, Lachnoclostridium, Blautia, and Acidaminococcaceae were positively correlated with disease-aggravating factors and negatively correlated with disease-alleviating factors. Overall, there was a strong correlation between intestinal microbiota abundance and disease factors. Sesamin effectively alleviates the symptoms and damage of allergic diarrhea by regulating the structure and metabolic activity of intestinal flora.

[0076] The evaluation of the anti-allergic diarrhea effect of the product containing sesamin according to the present invention based on the animal model shows that sesamin can regulate the differentiation balance of intestinal immune cells, inhibit the degranulation process of mast cells, and alleviate diarrhea symptoms such as watery stools and loose stools. Correlation analysis shows that there is a significant correlation between intestinal flora and short-chain fatty acids and between flora and disease factors. Sesamin can alleviate clinical symptoms by affecting the intestinal flora-short-chain fatty acid pathway. Sesamin treatment can increase the abundance of probiotics, reduce the number of pathogenic bacteria, and promote the generation of beneficial metabolites such as short-chain fatty acids, thereby effectively alleviating allergic diarrhea. Therefore, the sesamin-containing product provided by the present invention shows a good application prospect in alleviating allergic diarrhea.

[0077] The above description is only a preferred embodiment of the present application and is not intended to limit the present application. For those skilled in the art, the present application may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present application shall be included in the protection scope of the present application.

Claims

1. The application of sesamin in increasing the production of short-chain fatty acids is characterized in that: The sesamin described is a lignan compound in sesame seeds and / or pepper; The sesamin regulates the intestinal flora and thus increases the production of short-chain fatty acids.

2. The use according to claim 1, characterized in that: The intestinal flora includes probiotics that relieve allergic diarrhea and / or pathogenic bacteria that induce allergic diarrhea.

3. The use according to claim 2, characterized in that: The probiotics for alleviating diarrhea include at least one of Prevotellaceae and Muribacillus (Muribaculaceae); And / or, the pathogenic bacteria inducing allergic diarrhea include at least one of Bacteroides, Enterobacteriaceae, Fusobacteriaceae, Lachnoclostridium, Blautia and Acidaminococcaceae.

4. The use according to claim 1, characterized in that: The short-chain fatty acids are produced by intestinal flora through fermentation of incompletely digested polysaccharides; preferably, the short-chain fatty acids include at least one of acetic acid, propionic acid, butyric acid, isobutyric acid and isovaleric acid.

5. Use of sesamin in preparing a drug for treating allergic diarrhea, characterized in that: The sesamin described is a lignan compound present in sesame seeds and / or peppers; The sesamin mentioned above plays a role in regulating allergic diarrhea by increasing the production of short-chain fatty acids; Preferably, the use of sesamin in the preparation of a drug for alleviating intestinal barrier damage caused by allergic diarrhea; And / or, use of sesamin in the preparation of a drug for alleviating intestinal barrier damage caused by allergic diarrhea; And / or, use of sesamin in the preparation of a drug for alleviating imbalance in immune T cell differentiation caused by allergic diarrhea.

6. A drug for treating allergic diarrhea, characterized in that: The medicine comprises the sesamin according to claim 1 or 2 and a carrier for delivering sesamin.

7. The drug according to claim 6, characterized in that The carrier for delivering sesamin comprises at least one of nanoparticles, emulsions, capsules, compressed candies, gels and liposomes.

8. The drug according to claim 6, characterized in that The invention also comprises auxiliary materials, wherein the auxiliary materials include at least one of a filler, an emulsifier, a binder, a stabilizer, an anticaking agent, a flavoring agent and a thickener.

9. The drug according to claim 6, characterized in that The medicine contains an effective dose of 0.1wt.%-99.9wt.% of sesamin.

10. The drug according to claim 6, characterized in that The drug reduces the abnormally elevated transcription levels of Th2 cell marker gene Gata3 and Th17 cell marker gene Rorc, and increases the abnormally reduced transcription levels of Th1 cell marker gene T-bet and Treg cell marker gene Foxp3.